EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Oral β-lactam combinations are effective in vitro against Mycobacterium avium , regardless of clarithromycin susceptibility

Maiko Yoshikawa iD, Tomoyasu Nishimura iD, Kana Misawa, Rina Shimamura, Kenta Suzuki, Shoko Kashimura, Yuki Igarashi, Yuki Enoki, Kazuaki Taguchi, Naoki Hasegawa, Ho Namkoong, Kazuaki Matsumoto iD

Microbiology Spectrum · 2025

DOI: 10.1128/spectrum.02012-25 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Microbiology Spectrum, 2025. Verfasst von Maiko Yoshikawa und 11 weiteren Autor:innen. Beteiligte Einrichtung: Division of Pharmacodynamics, Keio University Faculty of Pharmacy, Minato-ku, Tokyo, Japan. Hauptthemen laut MEDLINE: Clarithromycin, Anti-Bacterial Agents, beta-Lactams, Mycobacterium avium Complex. Die Arbeit nennt 57 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Japan Society for the Promotion of Science, Japan Science and Technology Agency SPRING, the Shionogi Infectious Disease Research Promotion Foundation.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

The global incidence and prevalence of pulmonary disease caused by the Mycobacterium avium complex (MAC), mainly comprising M. avium and Mycobacterium intracellulare , is increasing. However, treating MAC pulmonary disease is challenging in cases of clarithromycin (CLR)-resistant MAC or where the patients experience adverse effects or drug interactions with the few available antibiotics. Therefore, developing novel and highly effective antibiotics against MAC is crucial. Although the efficacy of dual β-lactams against Mycobacterium abscessus has been receiving attention, the efficacy of dual β-lactams against MAC remains unclear. Here, we used MAC type strains and clinical isolates to determine whether dual β-lactams were effective against MAC and which combinations synergistically inhibited bacterial growth using a broth microdilution checkerboard assay with 6 oral and 22 intravenous antibiotics. The combination effect and antibacterial activity differed between M. avium and M. intracellulare . Five combinations of oral β-lactams and 78 combinations of intravenous β-lactams showed a synergistic effect against the M. avium type strain. Among the M. avium clinical isolates, faropenem combined with cefuroxime showed the highest synergistic effect, and amoxicillin combined with tebipenem showed the lowest minimum inhibitory concentration. There was no significant difference in the combination effects between the CLR-susceptible and CLR-resistant M. avium clinical isolates in these pairs. In conclusion, regardless of CLR susceptibility, the oral β-lactam combinations were effective against M. avium . Thus, when treating MAC pulmonary disease, it is crucial to determine whether M. avium or M. intracellulare is the cause. IMPORTANCE Mycobacterium avium complex causes chronic respiratory infections, but treatment is often limited by drug resistance, intolerance, or interactions. As new therapeutic strategies are urgently needed, we focused on β-lactam antibiotics, which are widely used and well tolerated. Although dual β-lactams are effective against Mycobacterium abscessus , their utility against Mycobacterium avium complex has remained largely unexplored. Our in vitro study revealed that several β-lactam combinations are effective against Mycobacterium avium , regardless of drug resistance, indicating potential for clinical use. In contrast, Mycobacterium intracellulare showed lower susceptibility to β-lactams. Given this difference in drug susceptibility, we emphasize the clinical need to distinguish Mycobacterium avium and Mycobacterium intracellulare to optimize treatment of Mycobacterium avium complex pulmonary disease.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

ClarithromycinAnti-Bacterial Agentsbeta-LactamsMycobacterium avium ComplexMycobacterium aviumMicrobial Sensitivity TestsHumansDrug SynergismMycobacterium avium-intracellulare InfectionAdministration, Oral

Stichwörter der Autor:innen

Mycobacterium avium complexmacrolide resistancenontuberculous mycobacteriatebipenemβ-lactam

Substanzen

ClarithromycinAnti-Bacterial Agentsbeta-Lactams

Autor:innen und Institutionen

  • Division of Pharmacodynamics, Keio University Faculty of Pharmacy, Minato-ku, Tokyo, Japan.
  • Department of Infectious Diseases, Keio University School of Medicine, Shinjuku-ku, Tokyo, Japan.
  • Keio University Health Center, Shinjuku-ku, Tokyo, Japan.
  • Department of Pharmacy, Okayama University, Okayama-shi, Okayama, Japan.
  • Graduate School of Biomedical and Health Sciences, Hiroshima University, Hiroshima-shi, Hiroshima, Japan.

ORCID-Profile: Maiko Yoshikawa, Tomoyasu Nishimura, Kazuaki Matsumoto

Förderung

  • Japan Society for the Promotion of Science
  • Japan Science and Technology Agency SPRING
  • the Shionogi Infectious Disease Research Promotion Foundation
  • the Japanese Society for Chemotherapy 70th Anniversary Research Support Program

Zitieren

APA

Yoshikawa, M., Nishimura, T., Misawa, K., Shimamura, R., Suzuki, K., Kashimura, S., Igarashi, Y., Enoki, Y., Taguchi, K., Hasegawa, N., Namkoong, H., & Matsumoto, K. (2025). Oral β-lactam combinations are effective in vitro against Mycobacterium avium , regardless of clarithromycin susceptibility. Microbiology Spectrum. https://doi.org/10.1128/spectrum.02012-25

Vancouver

Yoshikawa M, Nishimura T, Misawa K, Shimamura R, Suzuki K, Kashimura S, et al. Oral β-lactam combinations are effective in vitro against Mycobacterium avium , regardless of clarithromycin susceptibility. Microbiology Spectrum. 2025. doi:10.1128/spectrum.02012-25

BibTeX
@article{Yoshikawa2025,
  author = {Yoshikawa, Maiko and Nishimura, Tomoyasu and Misawa, Kana and Shimamura, Rina and Suzuki, Kenta and Kashimura, Shoko and Igarashi, Yuki and Enoki, Yuki and Taguchi, Kazuaki and Hasegawa, Naoki and Namkoong, Ho and Matsumoto, Kazuaki},
  title = {Oral β-lactam combinations are effective in vitro against Mycobacterium avium , regardless of clarithromycin susceptibility},
  journal = {Microbiology Spectrum},
  year = {2025},
  doi = {10.1128/spectrum.02012-25}
}
Kostenlos starten →